| | | | | | | | Welcome to Editors' (re)View, where Pharma Manufacturing editors handpick notable industry happenings that deserve some extra consideration. See what you may have missed this week in pharma. |
|
|
|
| |
| | |
|
|
| | | | | The drugmaker broke ground on a $223 million expansion, adding more than 100 jobs and new biologics capacity. |
|
|
| Dupixent is now the first and only medication in the U.S. for the treatment of eosinophilic esophagitis in patients ages 1 to 11. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
